Page 7 - சலீம் யூசுப் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dec 23, 2020 Participants without cardiovascular disease but who were at increased risk were randomly assigned to receive a polypill (i.e. 1 statin with 3 blood pressure-lowering drugs) or placebo and to receive aspirin or placebo. With 4.6 years follow-up, the incidence of cardiovascular events was lower among participants receiving both the polypill and aspirin than among those receiving both placebos. Physician’s Weekly interviews the lead study investigator, Prof. Salim Yusuf (Population Health Research Institute, Hamilton, Canada) who presented the results of the TIPS-3 trial at the American Heart Association Scientific Sessions 2020 [1].  TIPS-3 randomised 5,713 people, mostly of South Asian ancestry, who did not have cardiovascular disease but were classified as being at intermediate or high risk as measured by the INTERHEART Risk Score. The polypill contains 40 milligrams of simvastatin, 100 milligrams of atenolol, 25 milligrams of hydrochlorothiazide, and 10 milligram

United statesAmerican heart association scientific sessionsSalim yusuf population health research instituteSalim yusufPopulation health research instituteSouth asianNew england journalHeart outcomes prevention evaluationஒன்றுபட்டது மாநிலங்களில்அமெரிக்கன் இதயம் சங்கம் அறிவியல் அமர்வுகள்சலீம் யூசுப் பாப்யுலேஶந் ஆரோக்கியம் ஆராய்ச்சி நிறுவனம்சலீம் யூசுப்பாப்யுலேஶந் ஆரோக்கியம் ஆராய்ச்சி நிறுவனம்தெற்கு ஆசியபுதியது இங்கிலாந்து இதழ்இதயம் ஔட்கம்ஸ் ப்ரெவெந்ஶந் மதிப்பீடு